Mike Wittekind PhD

Prior to founding Olympic Protein Technologies, Mike served as the Chief Scientific Officer at ContraFect Corporation leading the team to build their discovery and development pipeline including CF-301 and CF-404 for the treatment of infectious diseases. Prior to that he served as the Executive Director of Research for Amgen Inc., where he directed the Protein Science Departments at the Amgen-Seattle and Amgen-Massachusetts sites leading discovery efforts for multiple protein therapeutics including antibodies, antibody-drug conjugates, bi-specifics, and protein fusions, as well as epitope mapping studies to support patent filings.

Under his direction 11 programs were transitioned from discovery to the preclinical and clinical stages, including brazikumab, AMG-820, tezupelumab, and brodalumab. Prior to that he held positions at Phylos Inc. and at Bristol-Myers Squibb Pharmaceutical Research Institute, directing groups at multiple sites leading protein expression and structural biology research for protein and small molecule therapeutic efforts including atazanavir. Mike received his Ph.D. in Biochemistry from the University of Wisconsin-Madison followed by postdoctoral studies at the University of Washington and is the author of over 40 peer-reviewed publications and 13 patents.